Transparency and acknowledgment

Operating programme Amount% on category% on total income
Grants  330.000,00  
 Astra Zeneca30.000,009,09%2,75%
 BI30.000,009,09%2,75%
 Chiesi30.000,009,09%2,75%
 Sanofi Genzyme30.000,009,09%2,75%
 Regeneron30.000,009,09%2,75%
 AbbVIe30.000,009,09%2,75%
 Roche30.000,009,09%2,75%
 OM Vifor Pharma30.000,009,09%2,75%
 Pfizer30.000,009,09%2,75%
 Viatris30.000,009,09%2,75%
 DBV Technologies30.000,009,09%2,75%
Honoraria for Advisors6.559,80  
 Honoraria for Advisors6.559,80 0,60%
Membership fees13.500,00  
 Membership fees13.500,00 1,24%
Deferred income 2023 for 2024 EFA Core activities-134.000,00  
Project programme    
EFA projects 606.742,00  
 Atopic Eczema Consensus AbbVie30.000,004,94%2,75%
 Atopic Eczema Consensus Sanofi/Regeneron115.000,0018,95%10,55%
 Breathe Chiesi40.000,006,59%3,67%
 Breathe Astra Zeneca66.200,0010,91%6,07%
 Breathe Roche30.000,004,94%2,75%
 Breathe Deferred income from 202290.000,0014,83%8,25%
 GUIDE Asthma deferred income from 202240.570,006,69%3,72%
 Interest Group Sanofi/Regeneron40.000,006,59%3,67%
 COPD Standards of Care Roche35.000,005,77%3,21%
 COPD Standards of Care Sanofi/Regeneron60.000,009,89%5,50%
 Capacity Building Astra Zeneca51.572,008,50%4,73%
 Capacity Building Deferred income from 20228.400,001,38%0,77%
 Deferred income 2023 to EFA Projects 2024-171.200,00  
EU projects 100.796,43  
 3TR5.443,635,40%0,50%
 ImmUniverse9.995,189,92%0,92%
 TOLIFE18.556,8618,41%1,70%
 SynAir-G52.417,0052,00%4,81%
 CURE14.383,7614,27%1,32%